Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.

Auteurs: Kloprogge F Workman L Borrmann S Tékété M Lefèvre G Hamed K Piola P Ursing J Kofoed PE Mårtensson A Ngasala B Björkman A Ashton M Friberg Hietala S Aweeka F Parikh S Mwai L Davis TME Karunajeewa H Salman S Checchi F Fogg C Newton PN Mayxay M Deloron P Faucher JF Nosten F Ashley EA McGready R van Vugt M Proux S Price RN Karbwang J Ezzet F Bakshi R Stepniewska K White NJ Guerin PJ Barnes KI Tarning J
Référence de l'article: PLoS medicine 2018 Jun ; 15(6); e1002579. doi: 10.1371/journal.pmed.1002579. Epub 2018 06 12


BACKGROUND: The fixed dose combination of artemether-lumefantrine (AL) is the most widely used treatment for uncomplicated Plasmodium falciparum malaria. Relatively lower cure rates and lumefantrine levels have been reported in young children and in pregnant women during their second and third trimester. The aim of this study was to investigate the pharmacokinetic and pharmacodynamic properties of lumefantrine and the pharmacokinetic properties of its metabolite, desbutyl-lumefantrine, in order to inform optimal dosing regimens in all patient populations.

METHODS AND FINDINGS: A search in PubMed, Embase,, Google Scholar, conference proceedings, and the WorldWide Antimalarial Resistance Network (WWARN) pharmacology database identified 31 relevant clinical studies published between 1 January 1990 and 31 December 2012, with 4,546 patients in whom lumefantrine concentrations were measured. Under the auspices of WWARN, relevant individual concentration-time data, clinical covariates, and outcome data from 4,122 patients were made available and pooled for the meta-analysis. The developed lumefantrine population pharmacokinetic model was used for dose optimisation through in silico simulations. Venous plasma lumefantrine concentrations 7 days after starting standard AL treatment were 24.2% and 13.4% lower in children weighing

CONCLUSIONS: Our findings suggest that revised AL dosing regimens for young children and pregnant women would improve drug exposure but would require longer or more complex schedules. These dosing regimens should be evaluated in prospective clinical studies to determine whether they would improve cure rates, demonstrate adequate safety, and thereby prolong the useful therapeutic life of this valuable antimalarial treatment.